Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03849118 · ClinicalTrials.gov registry record · Phase 3
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
A Phase 3 study, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT03849118: Completed Phase 3 study, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
NCT03849118 is a Phase 3 study that has completed, run by Telix Pharmaceuticals (Innovations) Pty Limited. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03849118, a Phase 3 study, has completed, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
Primary Outcome
This outcome was evaluated on all patients by using a PET/CT machine to determine the uptake of the Zr89 radiotracer within the renal lesion. This was compared against the histological determination of the lesion type following resection of the lesion
Interventions
- DIAGNOSTIC_TEST 89Zr-girentuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-08-15 |
| Est. Completion | 2022-11-07 |
| Phase | Phase 3 |
What the finished NCT03849118 record still lists
NCT03849118 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 1 intervention - of which 89Zr-girentuximab is the first listed.
NCT03849118 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03849118 about?
NCT03849118 is a clinical study titled "89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study". 89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
What is the current status of trial NCT03849118?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2019-08-15. Estimated completion is 2022-11-07.
What interventions are being tested in trial NCT03849118?
The interventions under investigation include: 89Zr-girentuximab (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03849118?
This trial is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03849118's enrollment target sits among peer trials
300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI